De-escalated Treatment Approach for Adult Ph-negative Acute Lymphoblastic Leukemia (ALL)

  • STATUS
    Recruiting
  • participants needed
    350
  • sponsor
    National Research Center for Hematology, Russia
Updated on 2 December 2022
lymphoid leukemia
methotrexate
cytarabine
flow cytometry
minimal residual disease
adult t-cell leukemia/lymphoma
residual tumor
ara-c

Summary

No high-dose methotrexate (MTX) and high-dose cytarabine (ARA-C) consolidation blocks, L-asparaginaseis scheduled for 1 year of treatment, 21 intrathecal injections through the whole treament, T-ALL patients in complete remossion (CR) after the informed consent are randomized to: auto-HSCT vs no auto-HSCT, - with the similar further maintenance. Stem cell harvest is performed after the 3rd consolidation by G-SCF disregarding minimal residual disease (MRD) level. Auto-HSCT is planned after the 5th consolidation phase. All primary bone samples are collected and tested for cytogenetics and molecular markers, all included patients are monitored by flow cytometry by aberrant immunophenotype in a centralized lab.

Description

  • 7 days prednisolone prephase
    • 8 weeks induction with de-escalation of induction chemotherapy: 3 instead of 4 dauno/vncr pulses,
      1. instead of 2 Cph injections during induction,
      2. instead of 4 ARA-C blocks, distribution of of L-asp injections through all phases
    • After CR achievement T-cell ALL patients are being randomized to auto-HSCT vs no auto-HSCT
    • Non-interruptive 5 consolidation phases with dose modification according to WBC and platelets count after CR achievement. Rotation of consolidation is permitted
    • After the 3rd consolidation stem cells harvesting is carried out for T-cell ALL patients randomized to auto-HSCT
    • Auto-HSCT after the 5th consolidation phase with non-myeloablative CEAM conditioning
    • 2 years maintenance for all patients
    • 21 TIT through the whole treatment with higher intensity during induction|consolidation
    • Centralized MRD monitoring at +70 d, + 133 d, + 190 days; before and after auto-HSCT
    • Allo-HSCT is planned only for very high risk patients (11q23 ALL, MRD positivity at day +190)

Details
Condition Precursor Cell Lymphoblastic Leukemia-Lymphoma
Treatment Autologous HSCT
Clinical Study IdentifierNCT03462095
SponsorNational Research Center for Hematology, Russia
Last Modified on2 December 2022

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note